OR
Speakers
Dr. Shaqil Kassam
This program has been made possible through unrestricted support from Ipsen
Studies/trials discussed:
- PROMID trial
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
- CLARINET study
- NETTER-1 trial
- NETTER-2 trial
- CLARINET forte phase 2 study
- CLARINET forte trial